Key Points
- Korro Bio CEO Ram Aiyar sold 15,152 shares on May 29 at an average price of $12.98, trimming his stake by 16.84%. The company said the sale was tied to tax withholding on vested equity awards.
- The stock fell 14.9% and opened at $11.00, while trading near its 50-day moving average of $12.37 and well below its 52-week high of $55.89. Korro Bio remains a small-cap biotech with a market value of about $158.6 million.
- Recent earnings were weak, with the company reporting a quarterly loss of $1.69 per share, missing estimates and reinforcing ongoing profitability concerns. Analysts still see upside on average, with a consensus rating of “Moderate Buy” and a $16.71 price target.
Korro Bio, Inc. (NASDAQ:KRRO - Get Free Report) CEO Ram Aiyar sold 15,152 shares of the business's stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $12.98, for a total value of $196,672.96. Following the completion of the transaction, the chief executive officer owned 74,848 shares in the company, valued at $971,527.04. The trade was a 16.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Korro Bio Stock Down 14.9%
Shares of NASDAQ KRRO opened at $11.00 on Wednesday. Korro Bio, Inc. has a twelve month low of $5.20 and a twelve month high of $55.89. The stock's 50 day moving average price is $12.37 and its 200-day moving average price is $10.63. The company has a market capitalization of $158.62 million, a PE ratio of -0.94 and a beta of 3.00.
Korro Bio (NASDAQ:KRRO - Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing analysts' consensus estimates of ($1.60) by ($0.09). Korro Bio had a negative return on equity of 117.86% and a negative net margin of 1,834.48%. As a group, research analysts expect that Korro Bio, Inc. will post -5.36 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities analysts recently commented on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Korro Bio in a research note on Wednesday, April 8th. Clear Str upgraded Korro Bio from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 18th. Citigroup assumed coverage on Korro Bio in a research note on Monday, May 18th. They issued a "buy" rating and a $21.00 price objective on the stock. William Blair upgraded Korro Bio from a "market perform" rating to an "outperform" rating in a research note on Tuesday, February 17th. Finally, Lifesci Capital upgraded Korro Bio to a "strong-buy" rating in a research note on Friday, May 29th. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $16.71.
Check Out Our Latest Stock Report on Korro Bio
Institutional Investors Weigh In On Korro Bio
Several institutional investors have recently made changes to their positions in KRRO. Geode Capital Management LLC lifted its position in shares of Korro Bio by 10.8% during the second quarter. Geode Capital Management LLC now owns 155,387 shares of the company's stock worth $1,941,000 after acquiring an additional 15,166 shares in the last quarter. Raymond James Financial Inc. lifted its position in shares of Korro Bio by 357.6% during the second quarter. Raymond James Financial Inc. now owns 83,392 shares of the company's stock worth $1,042,000 after acquiring an additional 65,170 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Korro Bio by 520.0% during the second quarter. Bank of America Corp DE now owns 28,156 shares of the company's stock worth $352,000 after acquiring an additional 23,615 shares in the last quarter. Wealth Forward LLC purchased a new stake in shares of Korro Bio during the third quarter worth $240,000. Finally, PNC Financial Services Group Inc. purchased a new stake in shares of Korro Bio during the third quarter worth $140,000. Hedge funds and other institutional investors own 13.18% of the company's stock.
Key Korro Bio News
Here are the key news stories impacting Korro Bio this week:
- Negative Sentiment: CEO Ram Aiyar sold 15,152 shares on May 29 at an average price of $12.98, reducing his ownership by 16.84%. The sale was disclosed as being tied to tax withholding on vested equity awards, but insider selling can still weigh on sentiment. SEC filing
- Negative Sentiment: Director Jean Francois Formela sold 2,860 shares on May 28 at $13.95, a transaction made under a pre-arranged 10b5-1 trading plan. While routine, the sale adds to the recent insider-selling overhang. SEC filing
- Neutral Sentiment: Lifesci Capital initiated/updated coverage with a “Strong-Buy” rating and published earnings estimates that are slightly better than the broader consensus for FY2026 through FY2030, which supports the long-term outlook but does not offset near-term losses.
- Negative Sentiment: The company’s most recent quarterly results missed EPS expectations, and Korro Bio continues to post sizable losses, reinforcing concerns about cash burn and profitability.
About Korro Bio
(
Get Free Report)
Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company's proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.
The company's pipeline features both engineered enzyme therapeutics and live biotherapeutics.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
